A Novel Therapeutic for Liver Fibrosis

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AA020163-01A1
Agency Tracking Number: R43AA020163
Amount: $269,158.00
Phase: Phase I
Program: SBIR
Awards Year: 2011
Solicitation Year: 2011
Solicitation Topic Code: NIAAA
Solicitation Number: PA10-050
Small Business Information
51 Charles Lindbergh Blvd, Uniondale, NY, -
DUNS: 53129065
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (516) 326-1200
Business Contact
Phone: (516) 326-1200
Email: igoldberg@angion.com
Research Institution
DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the treatment of liver fibrosis include changes in diet, life-style and/or medications to alleviate the underlying cause of disease. Since liver disease is typically diagnosed following significant scar formation, adjuvant strategies that oppose the molecular and cellular program of fibrosis that drives liver disease and activate matrix degrading pathways are urgently required. A preponderance of preclinical data in models of fibrotic liver disease speaks to the beneficial effects of the naturally occurring peptide hormone Relaxin (H2R). Translation of these findings into clinical regimen has been painfully slow in large part due to the costs and logistical difficulties associated with commercial production of recombinanthuman H2R. To fully capitalize on the antifibrotic potential of H2R, Angion Biomedica Corp., NY and Chemical and Biopharmaceutical Laboratories (CBL, CO) have developed a library of H2R-like peptides in commercially viable quantities at a fraction of thecost associated with production of similar quantities of recombinant human H2R. Importantly, our preliminary studies suggest that these novel peptides share H2R-like bioactivity in vitro. The proposed SBIR Phase I program seeks to identify a lead antifibrotic candidate from within this library as a treatment for liver fibrosis. PUBLIC HEALTH RELEVANCE: Fibrotic liver disease is a major health and socioeconomic burden in the United States. Development of a clinically viable antifibrotic strategy against liver disease is of tremendous significance.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government